TCF.L

TheraCryf plc
Theracryf PLC - Notice of Results
14th November 2024, 11:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2795M
Theracryf PLC
14 November 2024
 

A black background with blue letters Description automatically generated


TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

Notice of Interim results and Presentation via Investor Meet Company

 

Alderley Park, 14 November 2024 - TheraCryf plc (AIM: TCF), formerly Evgen Pharma plc, the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that the Company's unaudited interim results for the six months to 30 September 2024 will be released on Thursday 28 November 2024.

 

The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the Investor Relations section of the Company's website: www.theracryf.com/investors.

 

Huw Jones, CEO, and Toni Hänninen, CFO will provide a live presentation via the Investor Meet Company platform at 11am on Thursday 28 November 2024.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 27 November 2024, 09:00 GMT, or at any time during the live presentation. Investors who already follow TheraCryf plc on the Investor Meet Company platform will automatically be invited.

 

Investors can sign up to Investor Meet Company HERE.

 

-Ends-

Enquiries

TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO

+44 (0)1625 315 090
enquiries@theracryf.com

Cavendish Capital Markets (NOMAD and Broker)
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)

+44 (0)20 7220 0500

Vigo Consulting
 Rozi Morris

+44 (0)20 7390 0231
theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma* neurodevelopmental disorders, addiction, anxiety and narcolepsy [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. As well as a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF. 

For further information, please visit: www.theracryf.com 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORBIBMTMTBBBFI]]>
TwitterFacebookLinkedIn